Reviewer’s report

**Title:** Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS

**Version:** 2  **Date:** 1 October 2010

**Reviewer:** William CS Cho

**Reviewer’s report:**

**Major Compulsory Revisions:**

The manuscript is improved and can be considered for publication after the following revisions.

Actually the paper is already translated into English of the paper in “Cho WC. Research progress in SELDI-TOF-MS and its clinical applications. Chin J Biotech (Sheng Wu Gong Cheng Xue Bao) 2006, 22:871-876” being published by Elsevier via ScienceDirect with the same journal and page number.


As agreed from the authors that the sample size for the experiments is small. For the concern of proteomics work, is there any validation cohort of samples?

Similarly, for the inferred proteins related to MMD pathophysiology were found at ExPASy protein database. Are there any validation work being conducted?

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.